MSgoesHome: Digital Gait Analysis in the Home Environment of Patients With Multiple Sclerosis
Study Details
Study Description
Brief Summary
The aim of this study is the development of novel telemedical examination methods based on sensor-based gait analysis in patients with multiple sclerosis (MS). In a first step, the basic technical feasibility of measuring gait parameters in MS patients under standardized conditions in the clinic and in the home environment of the study participants will be investigated.
In a subsequent two-week study phase, gait parameters (real-life monitoring) and standardized gait tests will be continuously recorded in the home environment of the study participants. The comparability of the collected gait parameters from standardized gait tests and real-life monitoring to clinical scales (e.g. EDSS) will investigate the medical applicability of gait analysis as a target parameter in MS patients.
New algorithms for detecting indication-specific gait patterns from gait analysis in patients' daily lives and their possible changes over time (progression) will be explored and implemented into the study system. In addition, a patient app annotates the standardized gait tests and collects questionnaire-based data from the study participants during real-life monitoring. Via a study tablet, the data of the gait analysis and the patient app are transmitted to a study platform (Digital Patient Manager). The clinical assessment data (neurological examination, questionnaires) can be entered via a web front-end of the study platform and assigned to the patient via a pseudonym.
A further aim of this study is to validate the technology used for its applicability in the home environment. By means of structured interviews after the study phase, the study participants will be asked about compliance and adherence.
The following scientific questions will be investigated in this project:
(a) Is gait analysis a feasible and meaningful target parameter for MS centers? b) Are gait parameters from real-life monitoring suitable biomarkers for the detection of MS symptoms? c) Can gait parameters from standardized gait tests be compared with different testing environments (clinic / home environment)? d) How do gait parameters from standardized gait tests differ from gait data from real-life monitoring? e) How is the telemedical application for the collection of gait parameters evaluated by the patients? f) Can disease progression be detected using sensor-based gait parameters from the home environment?
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Study Group No intervention |
Outcome Measures
Primary Outcome Measures
- Number of detected gait cycles per patient per day [day 1 to day 14]
Number of sensor-detected gait cycles (one gait cycle are two steps) per patient per day
- Daily sensor wear time per patient [day 1 to day 14]
Percentage of sensor wear time per patient per day - range from 0 hours (0%) to 6 hours (100%)
- Completeness of days during 14-day field period per patient with sensor records [day 1 to day 14]
Percentage of days with sensor data recorded per patient - range from 0 days (0%) to 14 days (100%)
- System Usability Scale (SUS) [day 14 (closeout visit)]
SUS score per patient - range from 0 to 100 score points (Higher scores mean a better outcome.)
Secondary Outcome Measures
- Difference in time of 25-Foot-Walk-Test (25FWT) performed at home versus 25-Foot-Walk-Test (25FWT) performed at clinic [day 1]
Difference in time, measured in seconds, of 25FWT performed at home and performed at clinic
- Difference in time of 25-Foot-Walk-Test (25FWT) performed at home versus 25-Foot-Walk-Test (25FWT) performed at clinic [day 14]
Difference in time, measured in seconds, of 25FWT performed at home and performed in clinic
- Difference in gait parameters during 25-Foot-Walk-Test (25FWT) performed at home versus 25-Foot-Walk-Test (25FWT) performed at clinic [day 1]
Difference in gait parameters (gait length in cm, speed in m/s, contact angle in degree, swing-through phase in percent, standing phase in percent, lateral swing in cm, toe clearance in cm, lifting angle of toes in cm, impact intensity in g, variability of these parameters and symmetry between left and right foot) during 25FWT performed at home versus 25FWT performed at clinic
- Difference in gait parameters during 25-Foot-Walk-Test (25FWT) performed at home versus 25-Foot-Walk-Test (25FWT) performed at clinic [day 14]
Difference in gait parameters (gait length in cm, speed in m/s, contact angle in degree, swing-through phase in percent, standing phase in percent, lateral swing in cm, toe clearance in cm, lifting angle of toes in cm, impact intensity in g, variability of these parameters and symmetry between left and right foot) during 25FWT performed at home versus 25FWT performed at clinic
- Correlation of change of Expanded Disability Status Scale (EDSS) and change of 25-Foot-Walk-Test (25FWT) performed at home [day 1 and day 14]
Correlation of change of EDSS (range from 0.0 to 10.0, Lower scores mean a better outcome.) and change of time to execute 25FWT in seconds performed at home
- Correlation of change of Expanded Disability Status Scale (EDSS) and change of 25-Foot-Walk-Test (25FWT) performed at clinic [day 1 and day 14]
Correlation of change of EDSS (range from 0.0 to 10.0, Lower scores mean a better outcome.) and change of time to execute 25FWT in seconds performed at clinic
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Diagnosis of multiple sclerosis according to McDonald criteria
-
Expanded Disability Status Scale (EDSS) 1-6
-
Age > 18 years
-
Ability to speak and read
-
Ability to use an application running on a smart device
-
Patient informed consent
Exclusion Criteria:
-
Severe difficulty walking with frequent falls
-
Inability to walk at least 10 meters
-
Permanent use of a wheelchair
-
Severe spasticity
-
Cognitive impairment with inability to give consent to protocol
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Department of Neurology, University of Regensburg | Regensburg | Bavaria | Germany | 93053 |
Sponsors and Collaborators
- Medical Valley Digital Health Application Center GmbH
- Celgene Corporation
- NeuroSys GmbH
- Fraunhofer Institute for Integrated Circuits IIS
- Portabiles HealthCare Technologies GmbH
- University of Regensburg
Investigators
- Principal Investigator: Ralf Linker, Professor, Department of Neurology, University of Regensburg, Regensburg 93053, Germany
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- MV-dmac 3445707